The high new Rx% might be an aberration, but it could also likely be a result of the NEJM article that came out December 20th that put tyzeka in the front of some people's minds and the affect is starting to trickle down to new Rx.
Will be interesting to look for follow though in the next couple of weeks.
Jan11 numbers retreated from the prior week, and it remains to be seen if the Jan04 numbers were the start of a trend or an aberration. Please see separate post for rolling four-week scripts. (Data c/o rkrw.)
NRx=number of new prescriptions; TRx=number of total prescriptions (new+renewal). For recently launched drugs, the trend in NRx is an indicator of what can be expected for TRx with a modest time lag. NRx% and TRx% are calculated as NRx and TRx divided by the number of new and total prescriptions, respectively, for all drugs in the HBV category. (A prescription is counted as new whenever it is newly written, even if the patient is already taking the drug.)